Apple to gauge cost implications for moving some production from China
By Akshay Kedari  Date: 2019-06-21

Apple to gauge cost implications for moving some production from China

China is a major market for Apple as it secured 18% of its total revenue from the country in last quarter

Technology giant Apple has reportedly been preparing to restructure its supply chain and has requested its key suppliers to evaluate the implications and cost of shifting around 15 to 30% of production capacity from China to Southeast Asia.

Citing multiple sources, unresolved dispute over the Sino-U.S. trade has led to the company’s request, however, a trade resolution now shall not alter the decision of the company.

Apparently, there is a great risk for the iPhone maker for heavily depending on manufacturing in China. Fitch, a credit rating agency, said that Dell Technologies Inc., HP Inc and Apple are the companies who have a higher probability to be blacklisted by China in retaliation for the restrictions imposed on Huawei.

According to reliable sources, companies like Foxconn, Wistron Corp and Pegatron Corp that are key iPhone assemblers, Compal Electronics Inc. that makes iPad and Luxshare-ICT, Goertek and Inventec Corp that make AirPods have reportedly been asked to look for options outside of China.

India, Indonesia, Vietnam, Malaysia and Mexico are the few companies that are being considered, out of which Vietnam and India are among the favorites for smartphones, sources indicated.

Wedbush Securities’ analysts said that Apple could move 5%-7% of its iPhone productions to India by next 12-18 months. Considering the complexity and logistics involved, a minimum of 2-3 years would be required for 15% of iPhone production to move from China to other regions.

Seemingly, China is a major market as well as vital production center for Apple and its devices. The company reportedly gathered nearly 18% of its total revenue from China during the quarter ended March.

Sources said a group of over 30 people have been dispersed from Apple’s capital studies team to negotiate plans for production with the governments and the suppliers over the monetary incentives which could be offered to lure Apple manufacturers.

 

Source credit- https://www.reuters.com/article/us-apple-china-restructuring/apple-explores-moving-15-30-of-production-capacity-from-china-nikkei-idUSKCN1TK0XN

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Fibonacci Brands acquires Darwin from Harvest Health & Recreation
Fibonacci Brands acquires Darwin from Harvest Health & Recreation
By Akshay Kedari

Fibonacci Brands has recently announced the acquisition of Darwin from Harvest Health & Recreation (HARV.CN) as its foundation brand. Fibonacci is a leading player in the international cannabis industry. According to James George, founder of Fib...

GVN adds EVIT Center and Chumakov as its new Centers of Excellence
GVN adds EVIT Center and Chumakov as its new Centers of Excellence
By Akshay Kedari

The Global Virus Network (GVN), an international coalition of medical virologists, has recently announced the addition of Australian and Russian researchers. GVN is adding the Center for EVIT (Emerging Viruses, Inflammation & Therapeutics) of th...

Wind Point Partners takes over RTIC to expand business portfolio
Wind Point Partners takes over RTIC to expand business portfolio
By Akshay Kedari

American private equity firm, Wind Point Partners has recently signed an acquisition deal with the one of the biggest direct-to-consumer (D2C) eCommerce providers of drinkware, RTIC. Reportedly, RTIC is Wind Point’s third acquisition of a famil...

Novartis reveals positive data from Phase III ORION trials of inclisiran
Novartis reveals positive data from Phase III ORION trials of inclisiran
By Akshay Kedari

Swiss multinational pharmaceutical firm, Novartis has recently announced results from its Phase III ORION-10 and -11 studies that focus on assessing the individual responses of patients on lowering low-density lipoprotein cholesterol (LDL-C) with inc...

Medtronic to acquire Companion Medical to expand diabetes business
Medtronic to acquire Companion Medical to expand diabetes business
By Akshay Kedari

Medtronic plc, the global leader in medical technologies, has reportedly announced that it is planning to acquire insulin pen manufacturer Companion Medical. The acquisition gives Medtronic access to Companion Medical’s ‘InPen’, wh...